[ad_1]
In response to the Chinese vaccine company Cansino’s clarification announcement on the evening of August 27 that “the vaccine cooperation project with the National Research Council of Canada (NRC) has not yet been fully concluded,” the NRC he responded exclusively to the CBN reporter on the night of August 28. : “Since CanSino’s new crown vaccine cannot be delivered during the window, the window of opportunity for this cooperation has closed.”
The NRC reiterated in a statement issued to CBN reporters on Friday that China Customs has not approved the request to ship the CanSino vaccine candidate to Canada. Due to the delay in vaccine shipments, we should consider prioritizing vaccine cooperation with other partners.
The statement also indicated that the previous agreement between NRC and Cansino was reviewed and signed by Cansino’s Chinese partner, the Beijing Institute of Technology and the Chinese Ministry of Science and Technology, which is also Cansino’s financing provider.
However, after the agreement was signed, the vaccine transportation rules changed, resulting in the CanSino vaccines not being authorized to be shipped to Canada. The NRC told CBN reporters that it was not aware of the specific process for modifying the vaccine transportation rules.
“CanSino has published phase I and phase II clinical data in the authoritative journal” The Lancet “and has publicly stated that it has authorized other countries to conduct phase III clinical trials. That is, on this particular vaccine, CanSino and La The NRC’s window of cooperation has ended and the NRC is also changing its priority to work with other vaccine teams. “
However, CanSino does not appear to agree with the NRC’s statement that the vaccine cooperation between the two parties has ended, and issued an announcement saying that the news has misled investors. At the close of the market on Friday, Cansino’s shares in the Hong Kong shares and the Science and Technology Innovation Board suffered another sharp decline, falling more than 4% and 3% respectively.
According to recent CanSino documents submitted to regulatory agencies, the company’s Ad5-nCoV adenovirus vector vaccine has been urgently approved for use in specific populations before large-scale phase III clinical trials have been completed. , which makes it the first world emergency. Use one of the approved vaccines, ahead of American competitors.
At the same time, CanSino International Business Senior Vice President Pierre Morgon recently stated that the company is negotiating with several countries to obtain approval for vaccine distribution before conducting large-scale safety and efficacy trials. . However, it did not reveal which countries it specifically negotiated with.
Late-stage clinical trials typically require data from thousands to tens of thousands of participants. Public health experts said that before the completion of large-scale trials, volunteers should be extensively immunized to assess the potential health risks of the vaccine. However, in the urgent situation of global vaccine research and development, manufacturers in various countries are trying to get to the end as quickly as possible.
Mogon said that before the completion of clinical trials, the vaccine is now being promoted to millions of people, which will broaden understanding of the drug’s safety and efficacy. “This helps build a database on vaccine safety, and of course it can also build people’s confidence in vaccine safety.” He said: “If the vaccine proves to be effective in phase III clinical trials, then this may become a future promotion of vaccine supply contracts. Accelerator.”
According to the company’s test results published in the internationally renowned medical journal “The Lancet,” the adenovirus vector vaccine Ad5-nCoV can promote the immune response of vaccinators, and it did not appear in early human trials with smaller populations. Serious security risks.
CBN Advertising Cooperation, Click Here
This content is CBN original and copyright belongs to CBN. Without CBN’s written permission, it may not be used in any way, including reprinting, extracting, copying, or mirroring. CBN reserves the right to pursue the legal liability of the offender. If you need to obtain an authorization, please contact the CBN copyright department: 021-22002972 or 021-22002335; [email protected].
Author of the article Return to Sohu to see more
Editor:
Disclaimer: The opinions in this article only represent the author himself. Sohu is an information publishing platform. Sohu only provides storage space services.
[ad_2]